Zydus Cadila gets USFDA nod for Exemestane Tablet
New Delhi: Drug firm Zydus Cadila has received final approval from the US health regulator to market Exemestane tablets, used for the treatment of breast cancer. The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in the strength of 25 mg, Zydus Cadila said in a BSE filing.
The company said it will manufacture the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Quoting IMS Health data for August 2018, the company said the estimated sale for Exemestane tablets is USD 68.6 million.
Zydus Cadila has more than 220 approvals and so far filed over 330 abbreviated new drug applications (ANDAs).
Read Also: Zydus Cadila gets USFDA nod for Desoximetasone cream
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd